All In Biotech

Drug Trial Radar · NCT05378997

Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male and Female Volunteers to Investigate the Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds and in Patients With Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa

Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Apr 7, 2022

Primary completion

Mar 16, 2024

Study completion Mar 16, 2024

Sponsor

Lead sponsor
Xinnate ABIndustry
Sponsor type
Industry
Collaborators
Region Skane
First posted
May 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a three-part, Phase I, first-in-human study designed to evaluate the safety, tolerability, and potential systemic exposure of multiple topical doses of TCP-25. Part I includes healthy volunteers with acute epidermal wounds formed by the suction blister technique. Part II includes patients with non-healing leg ulcers and Part III patients with dystrophic epidermolysis bullosa (DEB).

Conditions

  • Blister
  • Wound of Skin
  • Epidermolysis Bullosa
  • Varicose Ulcer of Lower Limb

Interventions

  • TCP-25 gel 0.86 mg/ml or placebo gelDrug

    TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient

  • TCP-25 gel 2.9 mg/ml or placebo gelDrug

    TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient

  • TCP-25 gel 8.6 mg/ml or placebo gelDrug

    TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 15 days in Part I (modified endpoints & timeframes in Part II & III)
  2. Incidence of abnormal local reactions (Local tolerability)Time frame: Day 1 in Part I (modified endpoints & timeframes in Part II & III)
  3. Incidence of abnormal local reactions (Local tolerability)Time frame: Day 2 in Part I (modified endpoints & timeframes in Part II & III)
  4. Incidence of abnormal local reactions (Local tolerability)Time frame: Day 3 in Part I (modified endpoints & timeframes in Part II & III)
  5. Incidence of abnormal local reactions (Local tolerability)Time frame: Day 5 in Part I (modified endpoints & timeframes in Part II & III)
  6. Incidence of abnormal local reactions (Local tolerability)Time frame: Day 8 in Part I (modified endpoints & timeframes in Part II & III)
  7. Incidence of abnormal local reactions (Local tolerability)Time frame: Day 11 in Part I (modified endpoints & timeframes in Part II & III)
  8. Incidence of abnormal local reactions (Local tolerability)Time frame: Day 15 in Part I (modified endpoints & timeframes in Part II & III)
  9. Number of patients with clinically significant changes from baseline in electrocardiogram (ECG)Time frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)
  10. Number of patients with clinically significant changes from baseline in vital signs.Time frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)
  11. Number of patients with clinically significant changes from baseline in physical examinationsTime frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)
  12. Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 2 in Part I (modified endpoints & timeframes in Part II & III)
  13. Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 3 in Part I (modified endpoints & timeframes in Part II & III)
  14. Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 5 in Part I (modified endpoints & timeframes in Part II & III)
  15. Number of patients with clinically significant changes from baseline in safety laboratory parametersTime frame: During screening (baseline) and on day 11 in Part I (modified endpoints & timeframes in Part II & III)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Skåne University Hospital in Lund, Clinical Trial Unit

    Lund, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.